RAGE Biotech emerged from the School of Translational Medicine at Monash University and focuses on splice-switching oligonucleotide therapeutics aimed at the receptor for advanced glycation end products (RAGE), a key driver of inflammatory responses and tissue injury. Its lead candidate, RB042, is being developed for chronic obstructive pulmonary disease (COPD) and related inflammatory lung conditions. By harnessing a naturally occurring RAGE inhibitor produced in the lungs, the company seeks to block RAGE activation and thereby reduce inflammation and tissue damage. The newly raised funds will support advancing RB042 into first-in-human clinical studies and broaden the pipeline into additional inflammatory indications. RAGE Biotech’s strategy leverages Monash University’s research strengths and innovation ecosystem to translate academic discoveries into clinical applications. The A$29 million Series A provides the capital required for early clinical testing and further program expansion. No revenue or patient metrics have yet been disclosed, reflecting the company’s pre-clinical stage.

Total raised

$19M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2025